SCHEDULE: 1Globe Capital Amends Sinovac Biotech 13D Filing Amid Ongoing Litigation and Ownership Dispute

1Globe Capital LLC and 1Globe Biomedical (Hong Kong) Company Limited filed Amendment No. 6 to their Schedule 13D for Sinovac Biotech Ltd., correcting previous errors and providing updates on ongoing litigation regarding beneficial ownership and corporate governance.

Summary

• 1Globe Capital LLC and 1Globe Biomedical (Hong Kong) Company Limited filed Amendment No. 6 to their Schedule 13D for Sinovac Biotech Ltd., correcting a typographical error from Amendment No. 4 and supplementing disclosures that were inadvertently omitted from Amendment No. 5.
• The reporting persons collectively beneficially own 18,515,315 common shares of Sinovac Biotech Ltd., representing 32.3% of the class, calculated based on 57,281,861 shares outstanding as of December 31, 2017.
• The percentage of ownership calculation excludes shares purportedly issued after May 2018, such as Exchange Shares and Disputed PIPE, which are subjects of ongoing litigation.
• A civil action was filed on April 14, 2025, in the U.S. District Court for the District of Massachusetts by Vivo Capital Surplus Fund VIII, L.P. against 1Globe Capital LLC and Jiaqiang Li, alleging Section 13(d) disclosure violations.
• The allegations include failure to disclose information about Jiaqiang Li, aggregate beneficial ownership, formation of an alleged group, and plans/proposals regarding the Issuer.
• The defendants, 1Globe Capital LLC and Jiaqiang Li, intend to vigorously defend against these claims, asserting they are not supported by evidence and include falsified stories.
• Many of the current allegations relate to a 2018 SEC investigation that was resolved in a May 2020 settlement with 1Globe Capital LLC and Li, where they neither admitted nor denied findings.
• On June 30, 2025, the District Court denied Vivo's request for relief relating to governance outcomes and shareholder votes but granted, in part, preliminary relief requiring updated Schedule 13D disclosures.
• In response to the court order, 1Globe Capital LLC promptly filed Amendment No. 4, disclosing that the reporting persons began casting votes for the Special Meeting of shareholders on July 8, 2025.
• 1Globe Capital LLC and Jiaqiang Li plan to file a motion to dismiss and a motion to dissolve the current lawsuit, with 1Globe Capital LLC arguing the Section 13(d) claim is pre-empted or mooted by recent amendments.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the reporting persons achieved a partial win in court (denial of governance relief), the ongoing litigation and the need for multiple corrective amendments to the filing introduce uncertainty and reflect persistent legal challenges. The document is primarily a factual update on a legal matter rather than a positive or negative business development.

Positives

• The District Court denied Vivo Capital Surplus Fund VIII, L.P.'s request for relief relating to governance outcomes and shareholder votes, which is favorable for 1Globe Capital LLC and the current Board.
• 1Globe Capital LLC promptly filed Amendment No. 4 and Amendment No. 6 to comply with the District Court's preliminary relief order for updated Schedule 13D disclosures.

Negatives

• The reporting persons are subject to ongoing litigation initiated by Vivo Capital Surplus Fund VIII, L.P., alleging disclosure violations under Section 13(d) of the Securities Exchange Act of 1934.
• Amendment No. 6 was necessary to correct a typographical error in Amendment No. 4 and to include disclosures inadvertently omitted from Amendment No. 5, indicating issues with prior filing accuracy.
• The litigation mirrors a dismissed 2018 lawsuit and involves allegations previously addressed in a 2020 SEC settlement, suggesting persistent legal challenges for the reporting persons.

Risks

• Ongoing litigation with Vivo Capital Surplus Fund VIII, L.P. poses a risk of legal costs, potential adverse judgments, and continued scrutiny regarding beneficial ownership and disclosure compliance.
• The dispute over shares purportedly issued after May 2018 (Exchange Shares and Disputed PIPE) could impact the total shares outstanding and the reporting persons' percentage of ownership.
• The need for multiple amendments to the Schedule 13D due to errors and omissions highlights a risk of continued disclosure challenges and potential regulatory scrutiny.

Future Outlook

1Globe Capital LLC and Jiaqiang Li plan to vigorously defend against the civil action, including filing a motion to dismiss and a motion to dissolve the lawsuit. 1Globe Capital LLC intends to argue that the Section 13(d) claim has been pre-empted or rendered moot by the filing of Amendment No. 4 and subsequent amendments.

Management Comments

• "1Globe Capital LLC and Li intend to vigorously defend against these Plaintiff's claim, which they contend are not supported by evidence and include falsified stories."

Industry Context

This filing primarily concerns a specific beneficial ownership dispute and related litigation within Sinovac Biotech Ltd., rather than broader industry trends. It highlights the complexities of corporate control and shareholder activism, particularly in companies with diverse ownership structures and international legal entanglements.

Legal Proceedings

• A civil action was filed on April 14, 2025, by Vivo Capital Surplus Fund VIII, L.P. against 1Globe Capital LLC and Jiaqiang Li in the U.S. District Court for the District of Massachusetts (Civil Action No. 25-10914 (D. Mass.)), alleging Section 13(d) disclosure violations.
• The lawsuit mirrors a 2018 lawsuit filed by the same former management buyout group against the same defendants in Massachusetts, which was dismissed.
• The same plaintiff group has filed other actions in the U.S. District Court for the Southern District of New York and in the Hong Kong High Court against 1Globe Capital LLC and others, with their requests for preliminary relief uniformly dismissed.
• Allegations in the current lawsuit related to an SEC investigation in 2018 were included in a settlement between the SEC and 1Globe Capital LLC and Li, resolved in May 2020.
• On June 30, 2025, the District Court denied Vivo's request for 'relief relating to governance outcomes and shareholder votes' but granted, in part, preliminary relief requiring updated Schedule 13D disclosures.

Stakeholder Impact

• Shareholders are directly impacted by the ongoing litigation and beneficial ownership disputes, which can create uncertainty regarding corporate control and governance.
• The legal proceedings may incur significant costs for the company and the reporting persons, potentially affecting financial resources.
• The outcome of the litigation could influence the composition of the Board and future strategic direction of Sinovac Biotech Ltd.

Next Steps

• 1Globe Capital LLC and Jiaqiang Li plan to file a motion to dismiss the civil action.
• 1Globe Capital LLC and Jiaqiang Li plan to file a motion to dissolve the civil action.
• 1Globe Capital LLC will move to dismiss the Section 13(d) claim on grounds of pre-emption or mootness by Amendment No. 4 and subsequent amendments.

Key Dates

Keywords

Sinovac Biotech Ltd., 1Globe Capital LLC, Schedule 13D, Beneficial Ownership, SEC Filing, Litigation, Shareholder Dispute, Corporate Governance, Disclosure Violations, Common Shares